NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis - PubMed (original) (raw)

Review

. 2018 Jan 16;71(2):177-192.

doi: 10.1016/j.jacc.2017.11.014.

Sergio Fazio 2, Keith C Ferdinand 3, Henry N Ginsberg 4, Marlys L Koschinsky 5, Santica M Marcovina 6, Patrick M Moriarty 7, Daniel J Rader 8, Alan T Remaley 9, Gissette Reyes-Soffer 4, Raul D Santos 10, George Thanassoulis 11, Joseph L Witztum 12, Simhan Danthi 9, Michelle Olive 9, Lijuan Liu 9

Affiliations

Review

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Sotirios Tsimikas et al. J Am Coll Cardiol. 2018.

Abstract

Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD.

Keywords: aortic stenosis; cardiovascular disease; lipoprotein(a); metabolism; pathophysiology; therapy.

Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The other authors report no conflicts.

Figures

Central Illustration

Central Illustration. Global Prevalence of Elevated Lp(A) Levels, Metabolism of Lp(A) Ad Phenotypic Expression of Disease, and Unmet Needs In Lp(A) Pathophysiology

The top of the figure depicts the migration of the LPA gene, and its multiple apo(a) isoforms, out of Africa to the rest of the world. Due to differences in migration of different isoforms, as well as subsequent LPA gene remodeling of single nucleotide polymorphisms, the prevalence of Lp(a) plasma levels is variable. The estimates of prevalence of elevated Lp(a) (> 50 mg/dL or >125 nmol/L is given, based on current estimates of threshold prevalence. The middle panels depict the synthesis of both alleles of apo(a) and the subsequent assembly into Lp(a) with an LDL-like particle. Lp(a) is secreted into circulation and accumulates in vascular tissues and aortic valve leaflets over a lifetime. The clearance of Lp(a) is less well understood but a large portion is cleared via hepatic receptors, and a smaller portion by renal mechanisms and other unidentified pathways. On the bottom is a very brief summary of unmet needs in the understanding of Lp(a) pathophysiology.

References

    1. Tsimikas S. A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711. - PubMed
    1. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: An analysis of 431 239 patients. Arterioscler Thromb Vasc Biol. 2017;37:580–588. - PMC - PubMed
    1. Langsted A, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Kamstrup PR. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. J Clin Endocrinol Metab. 2016;101:3281–7. - PubMed
    1. Verbeek R, Boyer M, Boekholdt SM, et al. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. Arterioscler Thromb Vasc Biol. 2017;37:43–48. - PMC - PubMed
    1. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999–3058. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources